Metastasis-Directed Therapy May Delay ADT in Advanced Prostate Cancer
Metastasis-directed therapy (MDT) in selected patients with recurrent oligometastatic prostate cancer led to PSA responses in a majority of patients and delayed initiation of hormonal therapy by 18 months, a retrospective study showed. Overall, 77 of 124 patients had PSA declines of more than 50% with surgery or stereotactic body radiation therapy (SBRT). In particular, […]
SABR for Oligometastatic Cancer Turns in ‘Acceptable’ Rates of Toxicity
Stereotactic ablative radiotherapy (SABR) treatment for oligometastatic or oligoprogressive cancer appeared to come with “acceptable” rates of toxic effects, according to SABR-5 study results. Among a population of 381 patients in the phase II trial, and with a median follow-up of 25 months, rates of grade 2 or greater toxic effects were observed in 18.6%, […]